UniProt P51449
Nuclear receptor ROR-gamma (P51449)
Nuclear receptor ROR-gamma (UniProt P51449), EC 2.3.1.48: 245 experimental structures on GenesisL1, 124 ligands bound, 319 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P51449
- Protein
- Nuclear receptor ROR-gamma
- EC
- 2.3.1.48
- Experimental structures
- 245
- Predicted models
- 0
- Ligands
- 124
- Pockets
- 319 · 46 records with a druggable one
Structures
245 records of P51449 in the MolNFT archive: 245 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3B0W | Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with… | x-ray diffraction | A, B | — | — |
| 3B0W | Crystal structure of the orphan nuclear receptor ROR(GAMMA)T ligand- binding domain in complex with… | x-ray diffraction | A, B | — | — |
| 3KYT | Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand | x-ray diffraction | A | — | — |
| 3KYT | Crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand | x-ray diffraction | A | — | — |
| 3L0J | Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand | x-ray diffraction | A | — | — |
| 3L0J | Crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand | x-ray diffraction | A | — | — |
| 3L0L | Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand | x-ray diffraction | A, B | — | — |
| 3L0L | Crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand | x-ray diffraction | A, B | — | — |
| 4NB6 | Crystal structure of the ligand binding domain of RORC with T0901317 | x-ray diffraction | A, B | — | — |
| 4NB6 | Crystal structure of the ligand binding domain of rorc with T0901317 | x-ray diffraction | A, B | — | — |
| 4NIE | Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with… | x-ray diffraction | A, B | — | — |
| 4NIE | Crystal structure of the orphan nuclear receptor ROR(GAMMA)T ligand- binding domain in complex with… | x-ray diffraction | A, B | — | — |
| 4QM0 | Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist | x-ray diffraction | A, C | — | — |
| 4QM0 | Crystal structure of rorc in complex with a tertiary sulfonamide inverse agonist | x-ray diffraction | A, C | — | — |
| 4S14 | Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with… | x-ray diffraction | A | — | — |
| 4S14 | Crystal structure of the orphan nuclear receptor rorgamma ligand- binding domain in complex with… | x-ray diffraction | A | — | — |
| 4WLB | Crystal structure of RORc in complex with a partial inverse agonist compound | x-ray diffraction | A, B | — | — |
| 4WLB | Crystal structure of rorc in complex with a partial inverse agonist compound | x-ray diffraction | A, B | — | — |
| 4WPF | Crystal structure of RORc in complex with a phenyl sulfonamide agonist | x-ray diffraction | A, D | — | — |
| 4WPF | Crystal structure of rorc in complex with a phenyl sulfonamide agonist | x-ray diffraction | A, D | — | — |
| 4WQP | Crystal structure of rorc in complex with a benzyl sulfonamide inverse agonist | x-ray diffraction | A, B | — | — |
| 4XT9 | RORgamma (263-509) complexed with GSK2435341A and SRC2 | x-ray diffraction | A | — | — |
| 4XT9 | Rorgamma (263-509) complexed with GSK2435341A and SRC2 | x-ray diffraction | A | — | — |
| 4YMQ | X-ray co-structure of nuclear receptor ROR-GAMMAT + SRC2 peptide with a benzothiadiazole dioxide… | x-ray diffraction | A | — | — |
| 4YMQ | X-ray co-structure of nuclear receptor ror-gammat + SRC2 peptide with a benzothiadiazole dioxide… | x-ray diffraction | A | — | — |
| 4YPQ | Crystal structure of the ROR(gamma)t ligand binding domain in complex with… | x-ray diffraction | A | — | — |
| 4YPQ | Crystal structure of the ROR(GAMMA)T ligand binding domain in complex with… | x-ray diffraction | A | — | — |
| 4ZJR | RORgamma in complex with inverse agonist 48 | x-ray diffraction | A, B, C, D | 4P3 | 13 (best 0.81) |
| 4ZJR | Rorgamma in complex with inverse agonist 48 | x-ray diffraction | A, B, C, D | — | — |
| 4ZJW | RORgamma in complex with inverse agonist 16 | x-ray diffraction | A, B | 4P1 | 9 (best 0.84) |
| 4ZJW | Rorgamma in complex with inverse agonist 16 | x-ray diffraction | A, B | — | — |
| 4ZOM | Rorgamma in complex with inverse agonist 4J. | x-ray diffraction | A, B, C, D | — | — |
| 5APH | Ligand complex of RORg LBD | x-ray diffraction | A | — | — |
| 5APH | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5APJ | Ligand complex of RORg LBD | x-ray diffraction | A | — | — |
| 5APJ | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5APK | Ligand complex of RORg LBD | x-ray diffraction | A, B, D | — | — |
| 5APK | Ligand complex of rorg lbd | x-ray diffraction | A, B, D | — | — |
| 5AYG | Crystal Structure of the Human ROR gamma Ligand Binding Domain With 3g | x-ray diffraction | A, B | — | — |
| 5AYG | Crystal structure of the human ror gamma ligand binding domain with 3G | x-ray diffraction | A, B | — | — |
| 5C4O | Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | x-ray diffraction | A | — | — |
| 5C4O | Identification of a novel allosteric binding site for rorgt inhibitors | x-ray diffraction | A | — | — |
| 5C4S | Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | x-ray diffraction | A | 4Y5 | 5 (best 0.82) |
| 5C4S | Identification of a novel allosteric binding site for rorgt inhibitors | x-ray diffraction | A | — | — |
| 5C4T | Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | x-ray diffraction | A | 4Y6, SO4 | 4 (best 0.82) |
| 5C4T | Identification of a novel allosteric binding site for rorgt inhibitors | x-ray diffraction | A | — | — |
| 5C4U | Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | x-ray diffraction | A | 4Y7 | 5 (best 0.82) |
| 5C4U | Identification of a novel allosteric binding site for rorgt inhibitors | x-ray diffraction | A | — | — |
| 5EJV | RORy in complex with T090131718 and Coactivator peptide EBI96 | x-ray diffraction | A, B | 444 | — |
| 5EJV | Rory in complex with T090131718 and coactivator peptide EBI96 | x-ray diffraction | A, B | — | — |
| 5ETH | RORy in complex with inverse agonist 3. | x-ray diffraction | A, B | 5RT | — |
| 5ETH | Rory in complex with inverse agonist 3. | x-ray diffraction | A, B | — | — |
| 5G42 | Ligand complex of RORg LBD | x-ray diffraction | A | 4TU, NA | 3 (best 0.83) |
| 5G42 | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5G43 | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5G44 | Ligand complex of RORg LBD | x-ray diffraction | A | I6G, SWX, YTZ, NA | — |
| 5G44 | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5G45 | Ligand complex of RORg LBD | x-ray diffraction | A | A7W, NA | — |
| 5G45 | Ligand complex of rorg lbd | x-ray diffraction | A | — | — |
| 5G46 | Ligand complex of RORg LBD | x-ray diffraction | A | 6VD, NA | — |
185 records more on the page itself.
Ligands
- NA · Sodium ion · in 26 records
- L3E · 4-[(~{E})-[3-[2-chloranyl-6-(trifluoromethyl)phenyl]-5-(1~{H}-pyrrol-3-yl)-1,2-oxazol-4-yl]methylideneamino]benzoic acid · in 8 records
- MJE · 4-[1-[2,6-bis(chloranyl)phenyl]carbonyl-5-methyl-thieno[3,2-c]pyrazol-3-yl]benzoic acid · in 7 records
- 444 · N-(2,2,2-trifluoroethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl) ethyl]phenyl}benzenesulfonamide · in 5 records
- 4F1 · 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indazol-3-yl}benzoic acid · in 5 records
- CLR · Cholesterol · in 5 records
- HC3 · 25-hydroxycholesterol · in 5 records
- SO4 · Sulfate ion · in 5 records
- 4Y5 · 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-4-fluoro-1H-indazol-3-yl}-3-fluorobenzoic acid · in 3 records
- 6Q5 · Ursolic acid · in 3 records
- 8YB · ~{N}-[4-(3-chlorophenyl)-5-(2-chlorophenyl)carbonyl-1, 3-thiazol-2-yl]-2-(4-ethylsulfonylphenyl)ethanamide · in 3 records
- HCD · (3alpha,8alpha)-cholest-5-ene-3,20-diol · in 3 records
- MHQ · Desmosterol · in 3 records
- 4CX · N-[3'-cyano-4'-(2-methylpropyl)-2-(trifluoromethyl) biphenyl-4-yl]-2-[4-(ethylsulfonyl)phenyl]acetamide · in 2 records
- 6QP · 2-chloranyl-6-fluoranyl-~{N}-[(2~{R})-4-(4-fluorophenyl)sulfonyl-2-(hydroxymethyl)-2,3-dihydro-1, 4-benzoxazin-6-yl]benzamide · in 2 records
- 6QW · ~{N}-[[3-methyl-4-(4-methylsulfonylphenyl) phenyl]methyl]-~{N}-(2-methylpropyl)-1-phenyl-methanesulfonamide · in 2 records
- 79U · 4-[3-[2-chloranyl-6-(trifluoromethyl)phenoxy]-5-(dimethylcarbamoyl)indazol-1-yl]benzoic acid · in 2 records
- 82R · (1R,2S,4S,5'R,6R,7S,8R,9S,10R,12S,13S,16S,18S)-5',7,9, 13-tetramethylspiro[5-oxapentacyclo[10.8.0.0^{2, 9}.0^{4,8}.0^{13,18}]icosane-6,2'-oxane]-10,16-diol · in 2 records
- 87J · (S)-{4-chloro-2-methoxy-3-[4-(methylsulfonyl)phenyl]quinolin-6-yl}(1-methyl-1H-imidazol-5-yl)[6-(trifluoromethyl)pyridin-3-yl]methanol · in 2 records
- 88J · (S)-[4-chloro-2-(dimethylamino)-3-phenylquinolin-6-yl](1-methyl-1H-imidazol-5-yl)(pyridin-4-yl)methanol · in 2 records
- 8Y2 · 2-(4-ethylsulfonylphenyl)-~{N}-[4-(2-phenylmethoxypyridin-3-yl)thiophen-2-yl]ethanamide · in 2 records
- 8Y5 · ~{N}-[4-[2-[(3-cyanophenyl)methoxy]pyridin-3-yl]thiophen-2-yl]-2-(4-ethylsulfonylphenyl)ethanamide · in 2 records
- 921 · N-methyl-N'-(3-methylbut-2-en-1-yl)-N'-(3-phenoxyphenyl)-N-[trans-4-(pyridin-4-yl) cyclohexyl]urea · in 2 records
- 92A · N-[(2R)-3-(4-{[3-(4-chlorophenyl) propanoyl]amino}phenyl)-1-(4-methylpiperidin-1-yl)-1-oxopropan-2-yl]-4-methylpentanamide · in 2 records
- 98H · (5R,10S,13R,14R,17R)-17-((R,E)-7-hydroxy-6-methylhept-5-en-2-yl)-4,4,10,13,14-pentamethyl-1,2,5,6,10,11,12, 13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,7(4H)-dione · in 2 records
- 98N · (S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1R,4S)-4-(trifluoromethyl)cyclohexyl) methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide · in 2 records
- 99N · [(3~{S},8~{S},9~{S},10~{R},13~{R},14~{S},17~{R})-10,13-dimethyl-17-[(2~{R})-5-[[4-(2-morpholin-4-ylethoxy) phenyl]methylamino]-5-oxidanylidene-pentan-2-yl]-2,3, 4,7,8,9,11,12,14,15,16,17-dodecahydro-1~{H}-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate · in 2 records
- 9A0 · 2-[4-({[4-(ethylsulfonyl)phenyl]acetyl}amino)phenyl]-2-methyl-N-phenylpropanamide · in 2 records
- 9P6 · 2-[2-[1-~{tert}-butyl-5-(4-methoxyphenyl)pyrazol-4-yl]-1,3-thiazol-4-yl]-~{N}-(oxan-4-ylmethyl)ethanamide · in 2 records
- 9WA · (R)-(4-chloro-2-methoxy-3-{[4-(1H-pyrazol-1-yl) phenyl]methyl}quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)[6-(trifluoromethyl)pyridin-3-yl]methanol · in 2 records
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.